Revenue for Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's current revenue (TTM) is $3.71B USD. Revenue is the total income from selling goods or services before any expenses. Unlike net income (earnings), revenue does not subtract operating costs, taxes, or other charges. Figures are in USD; chart and tables below use historical filings (not a live revenue-per-second estimate).
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingRevenueSwitch metric
TTM (last 4 quarters)
$3.71B
YoY change
+65.2%
5Y CAGR
+49.8%
Peak year (2025)
$3.71B
Cumulative revenue
$11.27B
Revenue history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Revenue history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| Fiscal year | Period ended | Reported | Revenue | YoY |
|---|---|---|---|---|
| 2025 | $3.71B | +65.2% | ||
| 2024 | $2.25B | +23.0% | ||
| 2023 | $1.83B | +76.2% | ||
| 2022 | $1.04B | +22.9% | ||
| 2021 | $844.29M | +71.3% | ||
| 2020 | $492.85M | +124.3% | ||
| 2019 | $219.75M | +193.4% | ||
| 2018 | $74.91M | -16.7% | ||
| 2017 | $89.91M | +90.7% | ||
| 2016 | $47.16M | +14.8% | ||
| 2015 | $41.10M | -18.7% | ||
| 2014 | $50.56M | +7.2% | ||
| 2013 | $47.17M | -29.3% | ||
| 2012 | $66.72M | -19.4% | ||
| 2011 | $82.76M | -17.3% | ||
| 2010 | $100.04M | -0.5% | ||
| 2009 | $100.53M | +4.5% | ||
| 2008 | $96.16M | +88.9% | ||
| 2007 | $50.90M | +89.0% | ||
| 2006 | $26.93M | +371.1% | ||
| 2005 | $5.72M | +33.6% | ||
| 2004 | $4.28M | +2330.7% | ||
| 2003 | $176,000 | — | ||
| 2002 | $0 | — |
Revenue values are taken from Alnylam Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of Alnylam Pharmaceuticals (ALNY) revenue is $3.71B – surged 65.2% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Alnylam Pharmaceuticals revenue compounded at +49.8% per year, sustaining 7 straight years of year-over-year growth.
Across the available history, revenue reached its high of $3.71B in 2025 and its low of $0 in 2002.
Among 8 Healthcare peers, Alnylam Pharmaceuticals (ALNY) ranks 9th; the peer median for revenue is $65.09B.
Alnylam Pharmaceuticals Revenue by Year
Alnylam Pharmaceuticals Revenue 2025: $3.71B
Alnylam Pharmaceuticals revenue in 2025 was $3.71B, surged 65.2% from 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Revenue 2024: $2.25B
Alnylam Pharmaceuticals revenue in 2024 was $2.25B, grew 23.0% from 2023.
Alnylam Pharmaceuticals Revenue 2023: $1.83B
Alnylam Pharmaceuticals revenue in 2023 was $1.83B, surged 76.2% from 2022.
Alnylam Pharmaceuticals Revenue 2022: $1.04B
Alnylam Pharmaceuticals revenue in 2022 was $1.04B, grew 22.9% from 2021.
Alnylam Pharmaceuticals Revenue 2021: $844.29M
Alnylam Pharmaceuticals revenue in 2021 was $844.29M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers — Revenue
Companies in the same sector as Alnylam Pharmaceuticals, ranked by their latest revenue.
| Company | Revenue | Sector |
|---|---|---|
| UnitedHealth Group Incorporated (UNH) | $447.57B | Healthcare |
| Novo Nordisk A/S (NVO) | $309.06B | Healthcare |
| Johnson & Johnson (JNJ) | $94.19B | Healthcare |
| Eli Lilly and Company (LLY) | $65.18B | Healthcare |
| Merck & Co., Inc. (MRK) | $65.01B | Healthcare |
| AbbVie Inc. (ABBV) | $61.16B | Healthcare |
| AstraZeneca PLC (AZN) | $58.74B | Healthcare |
| Amgen Inc. (AMGN) | $36.74B | Healthcare |
Frequently asked questions
What is Alnylam Pharmaceuticals's revenue?
- Latest reported revenue for Alnylam Pharmaceuticals (ALNY) is $3.71B (period ending December 31, 2025).
How has Alnylam Pharmaceuticals revenue changed year-over-year?
- Alnylam Pharmaceuticals (ALNY) revenue changed +65.2% year-over-year on the latest annual filing.
What is the long-term growth rate of Alnylam Pharmaceuticals revenue?
- Alnylam Pharmaceuticals (ALNY) revenue compound annual growth rate is +49.8% over the most recent 5 years available.
When did Alnylam Pharmaceuticals revenue hit its highest annual value?
- Alnylam Pharmaceuticals revenue reached its highest annual value of $3.71B in 2025.
What was Alnylam Pharmaceuticals revenue in 2024?
- Alnylam Pharmaceuticals (ALNY) revenue in 2024 was $2.25B.
What was Alnylam Pharmaceuticals revenue in 2025?
- Alnylam Pharmaceuticals (ALNY) revenue in 2025 was $3.71B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
ALNY Overview
Company profile, financial tools, and key metrics
ALNY Revenue Counter
Earns $117.77 every second. See per minute, hour, and day.
ALNY Earnings Counter
Earns $9.95 per second net profit. See per minute, hour, and day.
ALNY Economic Scale
Exceeds Curacao's GDP. Compare with world economies.
ALNY What If Invested
What if you had invested $1,000? See historical returns from any date.
ALNY How It Makes Money
Discover visual breakdown of $3.71B in revenue — where it comes from and where it goes.
ALNY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ALNY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ALNY Daily Price Character
Explosive · 50.6% historical win rate (green days). Streaks & record days.
ALNY Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.